Title: Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance.
Journal: Journal of molecular biology 20170217
Title: Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20121215
Title: Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20120901
Title: Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells.
Journal: Molecular cancer therapeutics 20120701
Title: GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Journal: Molecular cancer therapeutics 20111201
Title: Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.
Journal: Journal of medicinal chemistry 20111110
Title: The emerging mechanisms of isoform-specific PI3K signalling.
Journal: Nature reviews. Molecular cell biology 20100501
Title: mTOR signaling at a glance.
Journal: Journal of cell science 20091015
Title: Defining the role of mTOR in cancer.
Journal: Cancer cell 20070701
Title: The phosphoinositide 3-kinase pathway.
Journal: Science (New York, N.Y.) 20020531
Title: Screening hospital admissions from the emergency department for occult carbon monoxide poisoning.
Journal: The American journal of emergency medicine 19900701
Title: Sutherlin DP, et al. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem, 2011, 54(21), 7579-7587.
Title: Wallin JJ, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther, 2011, 10(12), 2426-2436.
